KAIROS DISCOVERY

Kairos Discovery — Financial Ratios

Key financial indicators FY2023-2025

Financial Ratios Overview

Indicator	Formula	2022–2023	2024	2025*
Revenue				
Net revenue	*Income statement*	*N/A*	*N/A*	*N/A*
Total income (Grants + R&D tax credit)	*Grants + CIR*	308,042 €	239,768 €	214,553 €
Net profit / loss				
Net result for the period	*Income statement*	(325,676 €)	(267,554 €)	(434,339 €)
Total assets				
Total assets (Net)	*Balance sheet*	694,368 €	853,966 €	351,897 €
Margins				
Gross margin	*Gross profit / Revenue*	*N/A — zero revenue*	*N/A — zero revenue*	*N/A — zero revenue*
Operating margin	*EBIT / Total income*	-171.0 %	-228.2 %	-346.1 %
Net margin	*Net result / Total income*	-145.0 %	-184.6 %	-311.8 %
Leverage & capital structure				
Debt ratio	*Financial debt / Total assets*	65.4 %	75.7 %	163.3 %
Debt-to-equity ratio	*Financial debt / Equity*	8.4x	11.9x	*N/S — negative equity*
Liquidity & debt coverage				
Current ration	*Current assets / Current liabilities*	2.53x	1.79x	0.79x
Quick ratio	*(Current assets - Prepaid) / Current liabilities*	2.15x	1.59x	0.57x
Cash ratio	*Cash / Current liabilities*	1.75x	1.31x	0.26x
Acid test ratio	*(Cash + Receivables) / Current liabilities*	2.15x	1.59x	0.49x
Debt service coverage ratio	*EBITDA / Total debt service*	-8.9x	-5.2x	-6.8x
EBITDA				
EBITDA	*EBIT + Depreciation & amortisation*	(376,891 €)	(318,377 €)	(458,387 €)
Return on equity				
ROE	*Net result / Equity*	-602.3 %	-493.4 %	*N/S — negative equity*
Intangible assets ratio				
Intangible assets (Gross) / Total assets	*Gross intangibles / Total assets*	5.8 %	6.4 %	17.9 %
Intangible assets (Net) / Total assets	*Net intangibles / Total assets*	5.1 %	4.7 %	9.3 %

Pre-revenue stage company. *Kairos Discovery operates under a pure R&D investment model with no commercial revenue. Public grants and the French R&D tax credit (CIR) have funded approximately 30% of total operating expenses since inception — the remainder financed through equity rounds and non-dilutive debt.*

Negative equity (FY2025). *The negative shareholders' equity of (€350,571) reflects cumulative R&D expenditure since inception — a structural characteristic of early-stage biotech companies that carries no insolvency risk. The current €850,000 equity round, once closed, will mechanically restore positive shareholders' equity.*

Negative margins & EBITDA. *Operating losses reflect investment in drug discovery with no commercial infrastructure. Net loss remained broadly stable from FY2023 to FY2024, reflecting disciplined cost management despite headcount growth. The FY2025 increase reflects deliberate R&D acceleration.*

Debt service coverage ratio. *Negative DSCR reflects the absence of commercial revenues — not an inability to service debt. All repayments have been met on schedule. The Bpifrance loan (€300k) remains in its interest-only deferral period. The Caisse d'Épargne Rhône-Alpes loan (€100k, 6.75%, 36 months) will be fully repaid by May 2026.*

Liquidity ratios (FY2025). *Current ratio of 0.79x and acid test of 0.49x reflect accelerated R&D spending ahead of the current fundraising round — the primary rationale for the €850,000 equity raise, which will restore all liquidity ratios to comfortable levels.*